中外医疗
中外醫療
중외의료
China Foreign Medical Treatment
2015年
28期
140-141,144
,共3页
吉西他滨%奥沙利铂%胰腺癌%临床
吉西他濱%奧沙利鉑%胰腺癌%臨床
길서타빈%오사리박%이선암%림상
Gemcitabine%Oxaliplatin%Pancreatic cancer%Clinical
目的 探讨吉西他滨与奥沙利铂联合治疗胰腺癌的效果及安全性, 以便提供治疗依据. 方法 随机选取2011 年4月—2013年2月该院收治的80例胰腺癌患者作为研究对象,随机均分为对照组与实验组,对照组给予吉西他滨,实验组采用吉西他滨联合奥沙利铂治疗,治疗后观察对比两组的客观疗效、临床受益率、不良反应及生存率. 结果 实验组患者的客观有效率、临床收益率及两年后生存率显著高于对照组(P<0.05),但其不良反应率显著低于对照组(P<0.05). 结论 吉西他滨与奥沙利铂联合治疗胰腺癌的疗效确切,安全性高,提高了患者的远期生存率.
目的 探討吉西他濱與奧沙利鉑聯閤治療胰腺癌的效果及安全性, 以便提供治療依據. 方法 隨機選取2011 年4月—2013年2月該院收治的80例胰腺癌患者作為研究對象,隨機均分為對照組與實驗組,對照組給予吉西他濱,實驗組採用吉西他濱聯閤奧沙利鉑治療,治療後觀察對比兩組的客觀療效、臨床受益率、不良反應及生存率. 結果 實驗組患者的客觀有效率、臨床收益率及兩年後生存率顯著高于對照組(P<0.05),但其不良反應率顯著低于對照組(P<0.05). 結論 吉西他濱與奧沙利鉑聯閤治療胰腺癌的療效確切,安全性高,提高瞭患者的遠期生存率.
목적 탐토길서타빈여오사리박연합치료이선암적효과급안전성, 이편제공치료의거. 방법 수궤선취2011 년4월—2013년2월해원수치적80례이선암환자작위연구대상,수궤균분위대조조여실험조,대조조급여길서타빈,실험조채용길서타빈연합오사리박치료,치료후관찰대비량조적객관료효、림상수익솔、불량반응급생존솔. 결과 실험조환자적객관유효솔、림상수익솔급량년후생존솔현저고우대조조(P<0.05),단기불량반응솔현저저우대조조(P<0.05). 결론 길서타빈여오사리박연합치료이선암적료효학절,안전성고,제고료환자적원기생존솔.
Objective To study the the clinical efficacy and safety of gemcitabine combined with oxaliplatin in the treatment of pancreatic cancer, in order to provide treatment basis. Methods The 80 cases of pancreatic cancer patients in our hospital from April 2011to February 2013 were as research subjects and randomly divided into the control group and the experimental group. The control group was cured by gemcitabine, but the experimental group was given gemcitabine combined with oxaliplatin. The ob-jective response rate, clinical benefit rate, adverse reaction and survival rate were observed and compared between the two groups. Results The objective response rate, clinical benefit rate and survival rate after two years of the experimental group were signifi-cantly higher than those of the control group (P<0.05), but the rate of adverse events was significantly lower than the control group (P<0.05). Conclusion The efficacy of gemcitabine combined with oxaliplatin in the treatment of pancreatic cancer is accurate and safe, and improves the patient's long-term survival.
